S
IMRX icon

Sanofi’s Immuneering IMRX Stock Holding History

Sanofi’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.5M Hold
2,708,559
– – 2.53% 9
2026
Q1 		$14.3M Hold
2,708,559
– – 4.25% 7
2025
Q4 		$17.8M Hold
2,708,559
– – 5.74% 5
2025
Q3 		$19M Buy
+2,708,559
New +$14.1M 7.28% 5

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Sanofi's IMRX Position: Q2 2026 in Review

Sanofi held its Immuneering (IMRX) position steady in Q2 2026 at 2,708,559 shares worth $13.5M. The position accounts for 2.53% of the portfolio, ranked #9.

Sanofi first reported a position in IMRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $19M in Q3 2025. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Sanofi held 2,708,559 shares of Immuneering worth $13.5M as of Q2 2026.
  • Sanofi left its Immuneering share count unchanged in Q2 2026.
  • Immuneering made up 2.53% of Sanofi's portfolio in Q2 2026, its #9 holding.
  • Sanofi first reported a position in Immuneering in Q3 2025 and has held it in 4 quarters since.
  • Sanofi's Immuneering position peaked at $19M in Q3 2025.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Sanofi's 13F filing for Q2 2026, filed 28 Jul 2026.